|Day Low/High||2.25 / 2.35|
|52 Wk Low/High||2.01 / 11.62|
Blackberry's Flying Circus, Foolish Filmmaker, Celldex Shenanigans, Benmosche's Big Mouth and Chrysler's Conundrum highlight Gregg Greenberg's list of dumb things on Wall Street this week.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Celldex and Isis Pharma received warm embraces from analysts Monday.
Cramer isn't selling Celldex Therapeutics but he's only buying ExOne for speculation.
While others criticize, Cramer praised the Federal Reserve for not cutting back at a time when the government could shut down.
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the October 19th expiration.
Celldex Therapeutics was a winner within the health care sector, rising $1.41 (7.4%) to $20.36 on average volume
These stocks look poised to break out and trade higher from current levels.
Cramer likes DexCom, thinks Himax Technologies is a buy but wants you to avoid SunPower.
Cramer is bowled over by all the good news pushing stocks higher.
Not only are certain sectors hot, but so is the U.S. economy, Cramer said, and that means an interest rate hike is not far away.
While financial and energy sector strength boosted the broad index, the Nasdaq 100 is stuck in reversal mode, following Friday's selloff.
Celldex Therapeutics was a leading decliner within the drugs industry, falling $0.40 (-2.0%) to $19.55 on average volume
Patent Provides Broad-Based Intellectual Property Platform for CDX-1127
Celldex Therapeutics (Nasdaq:CLDX) is trading at unusually high volume Monday with 3.3 million shares changing hands. It is currently at two times its average daily volume and trading down 83 cents (-3.9%).
Speculation over Celldex's ultra-orphan drug candidate is the reason for the huge stock move.
Stocks with insider trader activity include ANF, MM, XCO, RNR and CLDX
Cramer thinks Six Flags is terrific and Kodiak Oil & Gas is a fine speculative stock.
The stock market is doing better than investors think, Cramer asserts.
Cramer is standing by Celldex Therapeutics but thinks Toll Brothers is in the penalty box.
Now that the Fed has spoken, Cramer said what will work best from here on out will be those companies that do better as the economy does better.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.